<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894435</url>
  </required_header>
  <id_info>
    <org_study_id>CT24</org_study_id>
    <nct_id>NCT04894435</nct_id>
  </id_info>
  <brief_title>Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity</brief_title>
  <acronym>MOSAIC</acronym>
  <official_title>Immunogenicity and Adverse Events Following Immunization With Alternate Schedules of Authorized COVID-19 Vaccines in Canada: MOSAIC Study (Mix and Match of the Second cOvid-19 Vaccine Dose for SAfety and ImmunogeniCity)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Immunization Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Center for Vaccinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BC Children's Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Research Institute of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ontario Agency for Health Protection and Promotion</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Interior Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Immunization Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goals of this study are to assess the immune response and safety of two different&#xD;
      vaccines for first and second doses as well as for differing intervals between the first and&#xD;
      second dose of two-dose vaccines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) are&#xD;
      two dose vaccines which were studied in schedules of either 0 and 21 days or 0 and 28 days,&#xD;
      respectively. The ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine is authorized to&#xD;
      be given in two doses one month to 12 weeks apart. We will compare the interval 0, 28 days to&#xD;
      a 0, 112 days (16 weeks) schedule, and assess the immunogenicity of both heterogeneous and&#xD;
      heterologous second doses using the Canadian schedule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1 - Moderna mRNA and Moderna mRNA - 28 days apart&#xD;
Group 2 - Moderna mRNA and Moderna mRNA - 16 weeks (112 days) apart&#xD;
Group 3 - Moderna mRNA and Pfizer/BioNTech mRNA - 28 days apart&#xD;
Group 4 - Moderna mRNA and Pfizer/BioNTech mRNA - 16 weeks (112 days) weeks apart&#xD;
Group 5 - Pfizer/BioNTech mRNA and Pfizer/BioNTech mRNA - 28 days apart&#xD;
Group 6 - Pfizer/BioNTech mRNA and Pfizer/BioNTech mRNA - 16 weeks (112 days) apart&#xD;
Group 7 - Pfizer/BioNTech mRNA and Moderna mRNA - 28 days apart&#xD;
Group 8 - Pfizer/BioNTech mRNA and Moderna mRNA - 16 weeks (112 days) apart&#xD;
Group 9 - AZ and Moderna mRNA - 28 days apart&#xD;
Group 10 - AZ and Moderna mRNA - 16 weeks (112 days) apart&#xD;
Group 11 - AZ and Pfizer/BioNTech - 28 days apart&#xD;
Group 12 - AZ and Pfizer/BioNTech - 16 weeks (112 days) apart</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants, laboratory staff, and statistical analysis personnel will be blinded to which vaccine they are receiving.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody response to SARS-CoV-2 S protein</measure>
    <time_frame>Day 56</time_frame>
    <description>The co-primary outcome for the non-inferiority comparison of 0, 28-day schedules with heterologous second dose is the immune response to SARS-CoV-2 at day 56 (28 days after the second dose of vaccine) based on anti-spike antibody titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody response to SARS-CoV-2 S protein</measure>
    <time_frame>Day 140</time_frame>
    <description>The co-primary outcome for the non-inferiority comparison of schedules in which the timing of the second dose of vaccine is different (0, 28 days v 0, 112 days) is the immune response to SARS-CoV-2 at day 140 (28 days after the last dose in the 0, 112 day schedule) based on anti-spike antibody titers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of antibody response to SARS-CoV-2 S over 12 months</measure>
    <time_frame>Baseline and Days 28, 56, 112, 140, 365</time_frame>
    <description>Assess durability of immune responses in each study group over 12 months based on anti-spike antibody titers and pseudoneutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pseudoneutralization assay, T cell testing, Antibody dependent cellular cytotoxicity (ADCC), Antibody avidity, RNA seq</measure>
    <time_frame>Days 28, 56, 112, 140, 365</time_frame>
    <description>Characterization of the immune response to COVID-19 vaccines in schedules with 0, 28 days versus 0, 112 days dosing and heterologous schedules to day 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt.</measure>
    <time_frame>From time of first study injection through Day 365.</time_frame>
    <description>Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of vaccines as determined by participant-completed questionnaire.</measure>
    <time_frame>Days 56, 140, and 365</time_frame>
    <description>Four 5 point likert scale type questions asking whether they would want to receive the vaccine again, recommend it to a friend, whether they were anxious about receiving it, and whether they would prefer a more painful injection if it conferred better protection.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group 1: Moderna, Moderna - 28 Days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Moderna, Moderna - 112 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine at 0.20 mg/mL via intramuscular injection in the deltoid muscle 112 days apart.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Moderna, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 28 days.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Moderna, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 112 days.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 112 days apart.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: Pfizer/BioNTech, Moderna - 28 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8: Pfizer/BioNTech, Moderna - 112 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9: Astra Zeneca, Moderna - 28 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10: Astra Zeneca, Moderna - 112 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 28 days.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 112 days.&#xD;
Vaccine-exposed participants will only be blinded to, and receive, the second injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273 SARS-CoV-2 vaccine</intervention_name>
    <description>Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.</description>
    <arm_group_label>Group 10: Astra Zeneca, Moderna - 112 days apart</arm_group_label>
    <arm_group_label>Group 1: Moderna, Moderna - 28 Days apart</arm_group_label>
    <arm_group_label>Group 2: Moderna, Moderna - 112 days apart</arm_group_label>
    <arm_group_label>Group 3: Moderna, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_label>Group 4: Moderna, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_label>Group 7: Pfizer/BioNTech, Moderna - 28 days apart</arm_group_label>
    <arm_group_label>Group 8: Pfizer/BioNTech, Moderna - 112 days apart</arm_group_label>
    <arm_group_label>Group 9: Astra Zeneca, Moderna - 28 days apart</arm_group_label>
    <other_name>COVID-19 Vaccine Moderna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2</intervention_name>
    <description>A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.</description>
    <arm_group_label>Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_label>Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_label>Group 3: Moderna, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_label>Group 4: Moderna, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_label>Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_label>Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_label>Group 7: Pfizer/BioNTech, Moderna - 28 days apart</arm_group_label>
    <arm_group_label>Group 8: Pfizer/BioNTech, Moderna - 112 days apart</arm_group_label>
    <other_name>Pfizer-BioNTech COVID-19 Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdOx1-S [recombinant]</intervention_name>
    <description>A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).</description>
    <arm_group_label>Group 10: Astra Zeneca, Moderna - 112 days apart</arm_group_label>
    <arm_group_label>Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_label>Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_label>Group 9: Astra Zeneca, Moderna - 28 days apart</arm_group_label>
    <other_name>Astra Zeneca COVID-19 Vaccine</other_name>
    <other_name>COVISHIELD AstraZeneca COVID-19 Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0, 28 day schedule</intervention_name>
    <description>Second injection administered 28 days post first injection</description>
    <arm_group_label>Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_label>Group 1: Moderna, Moderna - 28 Days apart</arm_group_label>
    <arm_group_label>Group 3: Moderna, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_label>Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart</arm_group_label>
    <arm_group_label>Group 7: Pfizer/BioNTech, Moderna - 28 days apart</arm_group_label>
    <arm_group_label>Group 9: Astra Zeneca, Moderna - 28 days apart</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0, 112 day schedule</intervention_name>
    <description>Second injection administered 112 days post first injection</description>
    <arm_group_label>Group 10: Astra Zeneca, Moderna - 112 days apart</arm_group_label>
    <arm_group_label>Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_label>Group 2: Moderna, Moderna - 112 days apart</arm_group_label>
    <arm_group_label>Group 4: Moderna, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_label>Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart</arm_group_label>
    <arm_group_label>Group 8: Pfizer/BioNTech, Moderna - 112 days apart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is willing and able to give written informed consent to participate in the&#xD;
             study&#xD;
&#xD;
          2. Age 18 years of age or older in good health or with mild or moderate stable&#xD;
             co-morbidities at the time of enrolment&#xD;
&#xD;
          3. Able and willing to complete all the scheduled study procedures during the whole study&#xD;
             follow-up period&#xD;
&#xD;
          4. If female of child-bearing potential and heterosexually active, has practiced adequate&#xD;
             contraception for 30 days prior to injection, has a negative pregnancy test on the day&#xD;
             of injection, and has agreed to continue adequate contraception until 3 months after&#xD;
             the second dose of study vaccine (Please refer to the definition section for a&#xD;
             description of child-bearing potential and adequate contraception)&#xD;
&#xD;
          5. Vaccine-exposed subgroups: have received or are booked to receive the first dose of an&#xD;
             authorized COVID-19 vaccine in the 57 days prior to Visit 1 (documentation of receipt&#xD;
             required), OR&#xD;
&#xD;
          6. Vaccine naïve subgroups: have not received an authorized COVID-19 vaccine at any time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability or unwillingness of participant or legally acceptable representative to give&#xD;
             written informed consent&#xD;
&#xD;
          2. Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or&#xD;
             immunosuppressant medication within the past 6 months except short term oral steroids&#xD;
             (≤14 days duration) or topical steroids&#xD;
&#xD;
          3. Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin)&#xD;
&#xD;
          4. Administration of immunoglobulins and/or any blood products within 3 months preceding&#xD;
             the first dose of study vaccine and for one month after the last dose of study vaccine&#xD;
&#xD;
          5. Allergy to any study vaccine or any active substance in a study vaccine&#xD;
&#xD;
          6. Bleeding disorder or history of significant bleeding following IM injections or&#xD;
             venipuncture&#xD;
&#xD;
          7. Continuous use of anticoagulants&#xD;
&#xD;
          8. A history of anaphylaxis to a previous vaccine&#xD;
&#xD;
          9. Pregnancy or intent to become pregnant during the study or within 3 months of the last&#xD;
             dose of study vaccine&#xD;
&#xD;
         10. History of laboratory-confirmed COVID-19 disease prior to enrolment by participant&#xD;
             report&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Langley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University/CIRN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Holmes</last_name>
    <phone>902-470-6854</phone>
    <email>melissa.holmes@dal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Mutch, RN</last_name>
    <phone>902-470-3860</phone>
    <email>jill.mutch@iwk.nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Royal Inland Hospital</name>
      <address>
        <city>Kamloops</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joyce Okofo Adjei</last_name>
      <phone>250-274-2995</phone>
      <email>joyce.okohoadjei@interiorhealth.ca</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Parfitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penticton Regional Hospital</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Keast</last_name>
      <phone>250-274-2995</phone>
      <email>susan.keast@interiorhealth.ca</email>
    </contact>
    <investigator>
      <last_name>Tom Oliver</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiffany Bursey</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lovelyn Charles</last_name>
      <phone>604-875-2187</phone>
      <email>mosaic.vec@bcchr.ubc</email>
    </contact>
    <investigator>
      <last_name>Manish Sadarangani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Research Institute of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Keijzer</last_name>
      <phone>204-789-3206</phone>
      <email>rkeijzer2@chrim.ca</email>
    </contact>
    <investigator>
      <last_name>Guillaume Poliquin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasaswini Palukuru</last_name>
      <phone>902-470-8141</phone>
      <email>ccfv@iwk.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Joanne Langley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute, University of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dodd</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>72310</phone_ext>
      <email>mosaicstudy@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Juthaporn Cowan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec, Université Laval</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo-Ann Costa</last_name>
      <phone>418-666-7000</phone>
      <phone_ext>10269</phone_ext>
      <email>recherche_vaccination@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Marc Dionne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>vaccine</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

